{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T19:21:18Z","timestamp":1762543278422,"version":"3.37.3"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T00:00:00Z","timestamp":1598572800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T00:00:00Z","timestamp":1598572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s00262-020-02708-3","type":"journal-article","created":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T06:02:22Z","timestamp":1598594542000},"page":"869-874","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Patterns of immune checkpoint protein expression in MYC-overexpressing aggressive B-cell non-Hodgkin lymphomas"],"prefix":"10.1007","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5077-4181","authenticated-orcid":false,"given":"Daniel J.","family":"Landsburg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexa","family":"Koike","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunita D.","family":"Nasta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakub","family":"Svoboda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen J.","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariusz A.","family":"Wasik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel C.","family":"Caponetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,28]]},"reference":[{"key":"2708_CR1","doi-asserted-by":"publisher","first-page":"3533","DOI":"10.1182\/blood-2009-05-220095","volume":"114","author":"KJ Savage","year":"2009","unstructured":"Savage KJ, Johnson NA, Ben-Neriah S, Connors JM, Sehn LH, Farinha P, Horsman DE, Gascoyne RD (2009) MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood 114:3533\u20133537. https:\/\/doi.org\/10.1182\/blood-2009-05-220095","journal-title":"Blood"},{"key":"2708_CR2","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1200\/JCO.2009.26.3947","volume":"28","author":"S Barrans","year":"2010","unstructured":"Barrans S, Crouch S, Smith A, Turner K, Owen R, Patmore R, Roman E, Jack A (2010) Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol 28:3360\u20133365. https:\/\/doi.org\/10.1200\/JCO.2009.26.3947","journal-title":"J Clin Oncol"},{"key":"2708_CR3","doi-asserted-by":"publisher","first-page":"3593","DOI":"10.1158\/1078-0432.CCR-15-2296","volume":"22","author":"ZY Xu-Monette","year":"2016","unstructured":"Xu-Monette ZY, Deng Q, Manyam GC et al (2016) Clinical and biologic significance of MYC genetic mutations in de novo diffuse large B-cell lymphoma. Clin Cancer Res 22:3593\u20133605. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2296","journal-title":"Clin Cancer Res"},{"key":"2708_CR4","doi-asserted-by":"publisher","first-page":"e33813","DOI":"10.1371\/journal.pone.0033813","volume":"7","author":"MJ Kluk","year":"2012","unstructured":"Kluk MJ, Chapuy B, Sinha P et al (2012) Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomas. PLoS ONE 7:e33813. https:\/\/doi.org\/10.1371\/journal.pone.0033813","journal-title":"PLoS ONE"},{"key":"2708_CR5","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s40880-017-0262-z","volume":"36","author":"LY Hu","year":"2017","unstructured":"Hu LY, Xu XL, Rao HL et al (2017) Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study. Chin J Cancer 36:94. https:\/\/doi.org\/10.1186\/s40880-017-0262-z","journal-title":"Chin J Cancer"},{"key":"2708_CR6","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1182\/blood-2015-02-629600","volume":"126","author":"J Kiyasu","year":"2015","unstructured":"Kiyasu J, Miyoshi H, Hirata A et al (2015) Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma. Blood 126:2193\u20132201. https:\/\/doi.org\/10.1182\/blood-2015-02-629600","journal-title":"Blood"},{"key":"2708_CR7","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1182\/blood-2017-11-742577","volume":"131","author":"SC Casey","year":"2018","unstructured":"Casey SC, Baylot V, Felsher DW (2018) The MYC oncogene is a global regulator of the immune response. Blood 131:2007\u20132015. https:\/\/doi.org\/10.1182\/blood-2017-11-742577","journal-title":"Blood"},{"key":"2708_CR8","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1002\/hon.2664","volume":"37","author":"MV Elbaek","year":"2019","unstructured":"Elbaek MV, Pedersen MO, Breinholt MF et al (2019) PD-L1 expression is low in large B-cell lymphoma with MYC or double-hit translocation. Hematol Oncol 37:375\u2013382. https:\/\/doi.org\/10.1002\/hon.2664","journal-title":"Hematol Oncol"},{"key":"2708_CR9","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.1200\/JCO.2011.41.0985","volume":"30","author":"NA Johnson","year":"2012","unstructured":"Johnson NA, Slack GW, Savage KJ et al (2012) Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 30:3452\u20133459. https:\/\/doi.org\/10.1200\/JCO.2011.41.0985","journal-title":"J Clin Oncol"},{"key":"2708_CR10","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1111\/his.12882","volume":"68","author":"D Kwon","year":"2016","unstructured":"Kwon D, Kim S, Kim PJ et al (2016) Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas. Histopathology 68:1079\u20131089. https:\/\/doi.org\/10.1111\/his.12882","journal-title":"Histopathology"},{"key":"2708_CR11","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25:579\u2013586. https:\/\/doi.org\/10.1200\/JCO.2006.09.2403","journal-title":"J Clin Oncol"},{"key":"2708_CR12","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","volume":"103","author":"CP Hans","year":"2004","unstructured":"Hans CP, Weisenburger DD, Greiner TC et al (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103:275\u2013282. https:\/\/doi.org\/10.1182\/blood-2003-05-1545","journal-title":"Blood"},{"key":"2708_CR13","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1007\/s11899-016-0320-7","volume":"11","author":"DJ Landsburg","year":"2016","unstructured":"Landsburg DJ (2016) Management of patients with MYC-altered lymphomas. Curr Hematol Malig Rep 11:208\u2013217. https:\/\/doi.org\/10.1007\/s11899-016-0320-7","journal-title":"Curr Hematol Malig Rep"},{"key":"2708_CR14","doi-asserted-by":"publisher","first-page":"20852","DOI":"10.1073\/pnas.0810958105","volume":"105","author":"M Marzec","year":"2008","unstructured":"Marzec M, Zhang Q, Goradia A et al (2008) Oncogenic kinase NPM\/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc Natl Acad Sci USA 105:20852\u201320857. https:\/\/doi.org\/10.1073\/pnas.0810958105","journal-title":"Proc Natl Acad Sci USA"},{"key":"2708_CR15","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1038\/leu.2017.103","volume":"31","author":"V Atsaves","year":"2017","unstructured":"Atsaves V, Tsesmetzis N, Chioureas D et al (2017) PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma. Leukemia 31:1633\u20131637. https:\/\/doi.org\/10.1038\/leu.2017.103","journal-title":"Leukemia"},{"key":"2708_CR16","doi-asserted-by":"publisher","first-page":"E10119","DOI":"10.1073\/pnas.1802166115","volume":"115","author":"M Kowanetz","year":"2018","unstructured":"Kowanetz M, Zou W, Gettinger SN et al (2018) Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1). Proc Natl Acad Sci USA 115:E10119\u2013E10126. https:\/\/doi.org\/10.1073\/pnas.1802166115","journal-title":"Proc Natl Acad Sci USA"},{"key":"2708_CR17","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s40425-019-0768-9","volume":"7","author":"AA Davis","year":"2019","unstructured":"Davis AA, Patel VG (2019) The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors. J Immunother Cancer 7:278. https:\/\/doi.org\/10.1186\/s40425-019-0768-9","journal-title":"J Immunother Cancer"},{"key":"2708_CR18","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1126\/science.aac9935","volume":"352","author":"SC Casey","year":"2016","unstructured":"Casey SC, Tong L, Li Y et al (2016) MYC regulates the antitumor immune response through CD47 and PD-L1. Science 352:227\u2013231. https:\/\/doi.org\/10.1126\/science.aac9935","journal-title":"Science"},{"key":"2708_CR19","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/s41379-018-0193-5","volume":"32","author":"L Li","year":"2019","unstructured":"Li L, Sun R, Miao Y et al (2019) PD-1\/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium Program. Mod Pathol 32:741\u2013754. https:\/\/doi.org\/10.1038\/s41379-018-0193-5","journal-title":"Mod Pathol"},{"key":"2708_CR20","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.3324\/haematol.2013.086173","volume":"98","author":"A Valera","year":"2013","unstructured":"Valera A, Lopez-Guillermo A, Cardesa-Salzmann T et al (2013) MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Haematologica 98:1554\u20131562. https:\/\/doi.org\/10.3324\/haematol.2013.086173","journal-title":"Haematologica"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-020-02708-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-020-02708-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-020-02708-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T23:33:28Z","timestamp":1630107208000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-020-02708-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,28]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["2708"],"URL":"https:\/\/doi.org\/10.1007\/s00262-020-02708-3","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"type":"print","value":"0340-7004"},{"type":"electronic","value":"1432-0851"}],"subject":[],"published":{"date-parts":[[2020,8,28]]},"assertion":[{"value":"4 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This protocol was approved by the Institutional Review Board of the University of Pennsylvania.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"A waiver of informed consent was granted by the Institutional Review Board of the University of Pennsylvania.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}